Evidence map›Paper›PMID 34123874›Full record

ArticleFrontiers in cellular and infection microbiology2021

RT-qPCR Assays for Rapid Detection of the N501Y, 69-70del, K417N, and E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants With Clinical Impact.

Natali Vega-Magaña, Rocío Sánchez-Sánchez, Jorge Hernández-Bello, Alberto Antony Venancio-Landeros, Marcela Peña-Rodríguez, Rosa Alejandra Vega-Zepeda, Byron Galindo-Ornelas, Mauricio Díaz-Sánchez, Mariel García-Chagollán, Gabriela Macedo-Ojeda and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 75 citations in OpenAlex.

  1. Dynamics of SARS-CoV-2 variants in southwest Ohio municipal wastewater.Environmental science : water research & technology · 2025
    Article
  2. Article
  3. Molecular characterization of SARS-CoV-2 nucleocapsid protein.Frontiers in cellular and infection microbiology · 2024
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Natali Vega-MagañaInstitute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara, Mexico.
Rocío Sánchez-SánchezResearch and Development Department, Genes2life (Grupo T), Irapuato, Mexico.
Jorge Hernández-BelloInstitute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara, Mexico.
Alberto Antony Venancio-LanderosBioinformatics Department, Genes2life (Grupo T), Irapuato, Mexico.
Marcela Peña-RodríguezLaboratory for the Diagnosis of Emerging and Reemerging Diseases (LaDEER), University Center for Health Sciences, University of Guadalajara, Guadalajara, Mexico.
Rosa Alejandra Vega-ZepedaResearch and Development Department, Genes2life (Grupo T), Irapuato, Mexico.
Byron Galindo-OrnelasResearch and Development Department, Genes2life (Grupo T), Irapuato, Mexico.
Mauricio Díaz-SánchezResearch and Development Department, Genes2life (Grupo T), Irapuato, Mexico.
Mariel García-ChagollánInstitute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara, Mexico.
Gabriela Macedo-OjedaInstitute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara, Mexico.
Octavio Patricio García-GonzálezResearch and Development Department, Genes2life (Grupo T), Irapuato, Mexico.
José Francisco Muñoz-ValleInstitute for Research in Biomedical Sciences (IICB), University Center for Health Sciences, University of Guadalajara, Guadalajara, Mexico.
Universidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several variants of the SARS-CoV-2 have been documented globally during the current COVID-19 pandemic. The N501Y, 69-70del, K417N, and E484K SARS-CoV-2 mutations have been documented among the most relevant due to their potential pathogenic biological effects. This study aimed to design, validate, and propose a fast real-time RT-qPCR assay to detect SARS-CoV-2 mutations with possible clinical and epidemiological relevance in the Mexican population. Methods: Targeting spike ( Results: In silico analyzes showed high specificity of the three assays. Amplicons of samples were confirmed through sequencing. The screening of samples of COVID-19 patients allowed the identification of the E484K mutation in nine individuals and the identification of P.2 Brazilian variant in Mexico. Conclusion: This work provides low-cost RT-qPCR assays for rapid screening and molecular surveillance of mutations with potential clinical impact. This strategy allowed the detection of E484K mutation and P.2 variant for the first time in samples from the Mexican population.

Indexed as

COVID-19SARS-CoV-2BrazilHumansMexicoMutationPandemicsSpike Glycoprotein, CoronavirusSpike Glycoprotein, CoronavirusE484Kepidemiological surveillancemolecular screeningP.2 variant detectionSARS-CoV-2SARS-CoV-2 mutationsSARS-CoV-2 mutation screening

Identifiers

PMID34123874
PMCPMC8195289
OpenAlexW3163145566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.